A phase IIb trial to investigate the efficacy of GALE-301/GALE-302 in ovarian cancer
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs GALE 301 (Primary) ; GALE 302 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 29 Dec 2017 According to a Sellas Life Sciences Group media release, SELLAS Life Science Group acquired Galena Biopharma, and subsequently Galena Biopharma changed its name to SELLAS Life Science Group.
- 20 Jan 2016 New trial record
- 13 Jan 2016 The company plans to initiate this trial in the second half of 2016, according to a Galena Biopharma media release.